News for Healthier Living

Immune Drug Anifrolumab Linked to Lower Risk of Infection and Hospitalization for Skin Lupus

Preliminary results from an investigator-initiated single-site clinical study show that some people with chronic cutaneous lupus erythematosus -- a type of lupus that can cause permanent skin damage and hair loss -- are less likely to acquire life-threatening infections when taking the drug anifrolumab, an FDA-approved monoclonal antibody treatment for systemic lupus erythematosus.

September 2, 2026


September 8 2026

September 7 2026

September 5 2026

September 4 2026

September 3 2026

September 2 2026

September 1 2026

August 31 2026

August 30 2026

August 29 2026

August 28 2026

August 27 2026

August 26 2026

August 25 2026